Staar Surgical Co (STAA) — SEC Filings

Staar Surgical Co (STAA) — 50 SEC filings. Latest: DEFA14A (Dec 19, 2025). Includes 20 DEFA14A, 18 8-K, 6 10-Q.

View Staar Surgical Co on SEC EDGAR

Overview

Staar Surgical Co (STAA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Dec 19, 2025: STAAR Surgical Company (STAAR) filed a DEFA14A on December 19, 2025, indicating that Alcon has exercised its right to require STAAR to repurchase certain shares. The filing is a definitive additional material, and no fee was required for this filing.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 46 neutral. The dominant filing sentiment for Staar Surgical Co is neutral.

Filing Type Overview

Staar Surgical Co (STAA) has filed 20 DEFA14A, 18 8-K, 6 10-Q, 1 10-K, 3 SC 13G/A, 1 8-K/A, 1 DEF 14A with the SEC between Apr 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent SEC Filings (50)

Staar Surgical Co SEC Filing History
DateFormDescriptionRisk
Dec 19, 2025DEFA14ASTAAR Surgical: Alcon Exercises Share Repurchase Rightmedium
Dec 17, 2025DEFA14ASTAAR Surgical Files Proxy Materialslow
Dec 16, 2025DEFA14ASTAAR Surgical Files Proxy Materialslow
Dec 11, 2025DEFA14ADEFA14A Filing
Dec 10, 2025DEFA14ASTAAR Surgical Files Proxy Materialslow
Dec 9, 20258-KSTAAR Surgical Files 8-K: Material Agreement & Exhibitslow
Dec 8, 20258-KSTAAR Surgical Files 8-Klow
Nov 17, 2025DEFA14ADEFA14A Filing
Nov 7, 20258-K8-K Filing
Nov 5, 202510-QSTAAR Surgical Swings to Loss Amid Alcon Merger Costs, Sales Diphigh
Oct 30, 2025DEFA14ASTAAR Surgical Co. Files Proxy Statement Supplementlow
Oct 28, 2025DEFA14ASTAAR Surgical Files Proxy Materialslow
Oct 27, 20258-KSTAAR Surgical Files 8-Klow
Oct 23, 20258-KSTAAR Surgical Files 8-Klow
Oct 20, 20258-KSTAAR Surgical Files 8-K on Financialslow
Oct 16, 2025DEFA14ASTAAR Surgical Files Definitive Additional Materialslow
Oct 14, 20258-KSTAAR Surgical to be Acquired by EssilorLuxottica for $5.7Bmedium
Oct 8, 2025DEFA14ASTAAR Surgical Files Definitive Proxy Materialslow
Oct 6, 2025DEFA14ASTAAR Surgical Files Definitive Additional Materialslow
Sep 30, 2025DEFA14AAlcon-STAAR deal clears HSR waiting periodmedium

Risk Profile

Risk Assessment: Of STAA's 43 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 28 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Staar Surgical Co Financial Summary (10-Q, Nov 5, 2025)
MetricValue
Revenue$181.641M
Net Income-$62.139M
Cash Position$176.155M

Key Executives

  • Chief Executive Officer
  • C. Robert Muchmore

Industry Context

The ophthalmic surgical device market, particularly for refractive procedures like those involving STAAR Surgical's lenses, is competitive and driven by technological innovation and patient demand for vision correction. Companies in this space often face rigorous regulatory scrutiny and require substantial R&D investment. The proposed merger with Alcon, a major player in the eye care industry, suggests a trend towards consolidation or strategic partnerships to gain market share and leverage scale.

Top Tags

proxy-statement (13) · sec-filing (10) · corporate-governance (5) · financials (5) · 8-k (4) · acquisition (4) · merger (4) · 10-Q (4) · ophthalmic-goods (3) · filing-update (3)

Key Numbers

Staar Surgical Co Key Metrics
MetricValueContext
Filing Date12/16/2025Date of DEFA14A filing
Press Release Date12/15/2025Date of press release included in filing
SEC File Number0-11634STAAR Surgical Company's SEC file number
EIN95-3797439STAAR Surgical Company's Employer Identification Number
IRS Employer Identification Number95-3797439Company identifier
Commission File Number0-11634Company identifier
Net Loss$62.139MFor nine months ended Sept 26, 2025, compared to $14.020M net income in prior year.
Net Sales$181.641MFor nine months ended Sept 26, 2025, down 31.4% from $264.951M in prior year.
Restructuring & Impairment Charges$27.938MFor nine months ended Sept 26, 2025, significantly impacting profitability.
Merger Transaction Costs$5.926MFor nine months ended Sept 26, 2025, related to the proposed Alcon merger.
Per Share Merger Price$28.00Cash offer from Alcon for each STAAR Surgical common stock share.
Cash and Cash Equivalents$176.155MAs of September 26, 2025, an increase from $144.159M at December 27, 2024.
Company Termination Fee$43.4MPotential fee STAAR Surgical may pay Alcon if merger agreement is terminated under specified circumstances.
Alcon Termination Fee$72.4MPotential fee Alcon may pay STAAR Surgical if merger agreement is terminated under certain circumstances.
Common Shares Outstanding49,741,953As of October 31, 2025.

Related Companies

ALC · ESLO

Frequently Asked Questions

What are the latest SEC filings for Staar Surgical Co (STAA)?

Staar Surgical Co has 50 recent SEC filings from Apr 2024 to Dec 2025, including 20 DEFA14A, 18 8-K, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of STAA filings?

Across 50 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 46 neutral. The dominant sentiment is neutral.

Where can I find Staar Surgical Co SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Staar Surgical Co (STAA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Staar Surgical Co?

Key financial highlights from Staar Surgical Co's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for STAA?

The investment thesis for STAA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Staar Surgical Co?

Key executives identified across Staar Surgical Co's filings include Chief Executive Officer, C. Robert Muchmore.

What are the main risk factors for Staar Surgical Co stock?

Of STAA's 43 assessed filings, 2 were flagged high-risk, 13 medium-risk, and 28 low-risk.

What are recent predictions and forward guidance from Staar Surgical Co?

Forward guidance and predictions for Staar Surgical Co are extracted from SEC filings as they are enriched.

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.